Established venous thromboembolism therapies: heparin, low molecular weight heparins, and vitamin K antagonists, with a discussion of heparin-induced thrombocytopenia.

@article{Pendleton2010EstablishedVT,
  title={Established venous thromboembolism therapies: heparin, low molecular weight heparins, and vitamin K antagonists, with a discussion of heparin-induced thrombocytopenia.},
  author={Robert C. Pendleton and George M Rodgers and Russell Douglas Hull},
  journal={Clinics in chest medicine},
  year={2010},
  volume={31 4},
  pages={
          691-706
        }
}
For a majority of patients with venous thromboembolism (VTE), initial treatment is straightforward and necessitates the immediate initiation of a parenteral anticoagulant (eg, heparin or low molecular weight heparin), simultaneous initiation of long-term therapy (eg, vitamin K antagonist), and discontinuation of the parenteral anticoagulant after 5 days assuming that the vitamin K antagonist is therapeutic. This standardized approach is based on numerous pivotal clinical trials completed over… CONTINUE READING
BETA